Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNOVATE
NCT04134260Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Apr 2020
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of apalutamide in prostate adenocarcinoma (2 arms), sponsored by NRG Oncology. Primary endpoint: Metastasis-Free Survival up to 7.5 years. Started Apr 2020; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT04134260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134260.